AdvanCell Closes Oversubscribed $112M Series C Funding AdvanCell, a pioneering clinical-stage radiopharmaceutical company focused on developing groundbreaking cancer therapeutics, has announced the successful closure of an oversubscribed US$112 million Series…
Cosette Pharmaceuticals a leading specialty pharmaceuticals company, has announced the appointment of Brad Leonard as Vice President, Generics Commercial Operations. This strategic move comes as the company continues its expansion…
Bayer has officially submitted a marketing authorization application to the European Medicines Agency (EMA), seeking approval for the use of finerenone in adult patients with heart failure (HF) with a…
Sionna Therapeutics Announces $150M IPO to Advance Cystic Fibrosis Drug Development Sionna Therapeutics, a Massachusetts-based biotechnology company specializing in cystic fibrosis (CF) treatments, has officially announced the terms of its…
Phase 3 Trial Pfizer has announced significant and positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER clinical trial. This trial assessed the efficacy of…
Inhalon Biopharma a clinical-stage biotechnology company focused on developing innovative treatments for acute respiratory infections (ARI), has announced a major milestone in the advancement of its inhaled antibody platform. The…
Median Technologies has announced a significant milestone in its mission to revolutionize lung cancer screening. The company’s proprietary artificial intelligence (AI) and machine learning (ML)-based software, eyonis™ Lung Cancer Screening…
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that it has secured a reimbursement agreement with NHS England, providing eligible sickle cell disease (SCD) patients access to its groundbreaking CRISPR/Cas9 gene-edited therapy,…
Galderma’s Breakthrough Findings Galderma (SWX:GALD), a global leader in dermatology, has announced the results of its Phase IIIb RELAX clinical trial, demonstrating the rapid onset, long-lasting efficacy, and high patient…
Poxel SA and Sumitomo Pharma: A Closer Look at TWYMEEG®’s Sales Performance and Strategic Growth Initiatives In the rapidly evolving landscape of metabolic disease treatments, Poxel SA (Euronext: POXEL –…
Ethris Reports Promising Phase 1 Data for mRNA Candidate ETH47 in Asthma Ethris GmbH, a pioneering biotechnology company specializing in next-generation RNA therapeutics and vaccines, has unveiled encouraging topline data…
Owkin Announces First Patient Dosed in Phase I Trial of OKN4395 for Solid Tumors Owkin, a leader in AI-driven biotech, has reached a significant milestone in its innovative journey with…